The impact of rarity in NICE’s health technology appraisals

BACKGROUND: In the absence of a framework designed to evaluate medicines for rare diseases in the UK, most orphan medicines are appraised by the National Institute for Health and Care Excellence (NICE) through the Single Technology Appraisal (STA) process. RESULTS: An analysis of STA appraisals of o...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Sophie, Ellis, Michelle, Brownrigg, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117316/
https://www.ncbi.nlm.nih.gov/pubmed/33985575
http://dx.doi.org/10.1186/s13023-021-01845-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117316/
https://www.ncbi.nlm.nih.gov/pubmed/33985575
http://dx.doi.org/10.1186/s13023-021-01845-x

Ejemplares similares